| MANNKIND CORP. NEW DL-,01 |
| USA |
| Gesundheit |
| US56400P7069 / A2DMZL |
| NNFN (Frankfurt) / MNKD (NASDAQ) |
| FRA:NNFN, ETR:NNFN, NNFN:GR, NASDAQ:MNKD |
| - |
| https://mannkindcorp.com/ |
|
MannKind Corporation is a biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic and orphan lung diseases. MannKind Corporation’s current product portfolio includes Afrezza, an inhaled insulin for adults w..
>Volltext.. |
| 944.45 Mio. EUR |
| 1229.49 Mio. EUR |
| 351.42 Mio. EUR |
| 31.11 Mio. EUR |
| -38.94 Mio. EUR |
| -0.13 EUR |
| 389.57 Mio. EUR |
| 47.25 Mio. EUR |
| -7.34 Mio. EUR |
| 0.78 |
| 34.56% |
| -237.16% |
| - |
| - |
| - |
| MANNKIND |
| 10.10.26 |